Tacrolimus and Temovate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tacrolimus (tacrolimus) and Temovate (clobetasol propionate). Common drug interactions include colitis among females and graft versus host disease among males.

The phase IV clinical study analyzes what interactions people have when they take Tacrolimus and Temovate. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,160 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Temovate?

Temovate has active ingredients of clobetasol propionate. eHealthMe is studying from 1,392 Temovate users. Check the latest studies of Temovate.



On Jul, 07, 2026

19 people who take Tacrolimus and Temovate together, and have interactions are studied.

Tacrolimus and Temovate drug interactions.

What are the common drug interactions of Tacrolimus and Temovate, by gender? *:

female:

  1. Colitis (inflammation of colon)
  2. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  3. Acute respiratory failure
  4. Bronchitis viral (inflammation of the mucous membrane in the bronchial tubes due to infection with streptococcus pneumoniae)
  5. Dyspnoea (difficult or laboured respiration)
  6. Hypoxia (low oxygen in tissues)
  7. Obstructive airways disorder (a progressive disease that makes it hard to breathe)
  8. Sepsis (a severe blood infection that can lead to organ failure and death)
  9. Sinusitis (inflammation of sinus)
  10. Wheezing (a high-pitched whistling sound made while you breath)

male:

  1. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  2. Chronic kidney disease
  3. Depression
  4. Nephrogenic anaemia (anaemia due to kidney disease)
  5. Respiratory tract infection
  6. Secondary hyperthyroidism
  7. Renal failure (kidney dysfunction)
  8. Death
  9. Lymphadenitis (inflammation or enlargement of a lymph node)
  10. Acute left ventricular failure (heart attack)

What are the common drug interactions of Tacrolimus and Temovate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Lymphadenitis (inflammation or enlargement of a lymph node)
  2. Adrenal suppression (suppression of cortisol secretion by the adrenal glands)
  3. Blood immunoglobulin e increased
  4. Respiratory tract infection

10-19:

  1. Colitis (inflammation of colon)
  2. Abdominal pain lower
  3. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)

20-29:

n/a

30-39:

  1. Acute respiratory failure
  2. Agitation (state of anxiety or nervous excitement)
  3. Chronic kidney disease
  4. Depression
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Renal failure (kidney dysfunction)
  7. Acute left ventricular failure (heart attack)

40-49:

  1. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  2. Chronic kidney disease
  3. Rash
  4. Renal failure (kidney dysfunction)
  5. Secondary hyperthyroidism

50-59:

n/a

60+:

  1. Death
  2. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  3. Injection site pain
  4. Pruritus (severe itching of the skin)

What are the existing conditions these people have? *

  1. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 6 people, 31.58%
  2. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 5 people, 26.32%
  3. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 21.05%
  4. Blood Iron Decreased: 4 people, 21.05%
  5. Nausea (feeling of having an urge to vomit): 4 people, 21.05%
  6. Constipation: 4 people, 21.05%
  7. Chronic Myeloid Leukaemia (In Remission): 2 people, 10.53%
  8. High Blood Pressure: 2 people, 10.53%
  9. Psoriasis (immune-mediated disease that affects the skin): 2 people, 10.53%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and Temovate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tacrolimus and Temovate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Temovate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tacrolimus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Temovate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus and clobetasol propionate (the active ingredients of Tacrolimus and Temovate, respectively), and Tacrolimus and Temovate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: